Nikita Ermolaev, Robin Willixhofer, Christoph Krall, Christina Kronberger, René Rettl, Christina Binder, Franz Duca, Christian Nitsche, Andreas Kammerlander, Michael Poledniczek, Bernhard Gregshammer, Diana Ahmadi-Fazel, Mahshid Eslami, Luciana Camuz Ligios, Johannes Kastner, Jutta Bergler-Klein, Roza Badr Eslam
{"title":"Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis.","authors":"Nikita Ermolaev, Robin Willixhofer, Christoph Krall, Christina Kronberger, René Rettl, Christina Binder, Franz Duca, Christian Nitsche, Andreas Kammerlander, Michael Poledniczek, Bernhard Gregshammer, Diana Ahmadi-Fazel, Mahshid Eslami, Luciana Camuz Ligios, Johannes Kastner, Jutta Bergler-Klein, Roza Badr Eslam","doi":"10.31083/RCM26081","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been found to have potential hematopoietic effects in patients with heart failure (HF). However, these benefits have not been studied in patients with cardiac amyloidosis (CA). CA patients present with HF symptoms and often suffer from iron deficiency, which has a negative impact on erythropoiesis and leads to lower hemoglobin and hematocrit levels. We sought to determine the potential effects of SGLT2i on hematological parameters and functional capacity (FC) in CA patients.</p><p><strong>Methods: </strong>A prospective analysis was conducted to compare the effects of SGLT2i in patients who received the best medical therapy (BMT) along with SGLT2i (n = 20), versus patients receiving only BMT without SGLT2i (n = 20) (historical control group). All patients underwent blood testing and cardiopulmonary exercise testing (CPET) at baseline (BL) and after 6 months [interquartile range (IQR): 4.0 to 8.0].</p><p><strong>Results: </strong>The SGLT2i-based therapy resulted in a significant improvement and difference in hematological parameters at 6 months follow-up compared to the control group. In the SGLT2i group, the mean hemoglobin level increased (+1.2 mg/dL), whereas in the control group, it decreased (-0.8 g/dL) (<i>p</i> < 0.001 for overall group comparison). The hematocrit showed a significant increase in the SGLT2i group (+4.4%) compared to a decrease in the control group (-1.8%) (<i>p</i> < 0.001). Additionally, the serum iron level improved in the SGLT2i-treated group (+ 5.5 [-5.0 to 17.5] μg/dL vs. -6.0 [-15.0 to 4.0] μg/dL, <i>p</i> = 0.121). Although there was no significant change in the peak oxygen consumption (peak VO<sub>2</sub>, (mL/min)/kg) (<i>p</i> = 0.206), as well as in pulmonary ventilation (VE)/carbon dioxide production (VCO<sub>2</sub>) slope in both groups (<i>p</i> = 0.964), the SGLT2i group maintained a peak VO<sub>2</sub> and VE/VCO<sub>2</sub> slope throughout the study.</p><p><strong>Conclusions: </strong>SGLT2i therapy improved hematological parameters and stabilized the FC of CA patients.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":"26 3","pages":"26081"},"PeriodicalIF":1.9000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951278/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in cardiovascular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/RCM26081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have been found to have potential hematopoietic effects in patients with heart failure (HF). However, these benefits have not been studied in patients with cardiac amyloidosis (CA). CA patients present with HF symptoms and often suffer from iron deficiency, which has a negative impact on erythropoiesis and leads to lower hemoglobin and hematocrit levels. We sought to determine the potential effects of SGLT2i on hematological parameters and functional capacity (FC) in CA patients.
Methods: A prospective analysis was conducted to compare the effects of SGLT2i in patients who received the best medical therapy (BMT) along with SGLT2i (n = 20), versus patients receiving only BMT without SGLT2i (n = 20) (historical control group). All patients underwent blood testing and cardiopulmonary exercise testing (CPET) at baseline (BL) and after 6 months [interquartile range (IQR): 4.0 to 8.0].
Results: The SGLT2i-based therapy resulted in a significant improvement and difference in hematological parameters at 6 months follow-up compared to the control group. In the SGLT2i group, the mean hemoglobin level increased (+1.2 mg/dL), whereas in the control group, it decreased (-0.8 g/dL) (p < 0.001 for overall group comparison). The hematocrit showed a significant increase in the SGLT2i group (+4.4%) compared to a decrease in the control group (-1.8%) (p < 0.001). Additionally, the serum iron level improved in the SGLT2i-treated group (+ 5.5 [-5.0 to 17.5] μg/dL vs. -6.0 [-15.0 to 4.0] μg/dL, p = 0.121). Although there was no significant change in the peak oxygen consumption (peak VO2, (mL/min)/kg) (p = 0.206), as well as in pulmonary ventilation (VE)/carbon dioxide production (VCO2) slope in both groups (p = 0.964), the SGLT2i group maintained a peak VO2 and VE/VCO2 slope throughout the study.
Conclusions: SGLT2i therapy improved hematological parameters and stabilized the FC of CA patients.
期刊介绍：
RCM is an international, peer-reviewed, open access journal. RCM publishes research articles, review papers and short communications on cardiovascular medicine as well as research on cardiovascular disease. We aim to provide a forum for publishing papers which explore the pathogenesis and promote the progression of cardiac and vascular diseases. We also seek to establish an interdisciplinary platform, focusing on translational issues, to facilitate the advancement of research, clinical treatment and diagnostic procedures. Heart surgery, cardiovascular imaging, risk factors and various clinical cardiac & vascular research will be considered.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
